Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

243Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

Abstract

Aim: To find an effective symptomatic treatment for osteogenesis imperfecta (OI). Methods: In a prospective observational study disodium pamidronate (APD) was given as monthly intravenous infusions to 28 children and adolescents (aged 0.6-18 years) with severe OI or a milder form of the disease, but with spinal compression fractures. Results: During treatment for 2-9 years, dual energy x ray absorptiometry measurements of the total body and of the lumbar spine showed a gradual increase in bone density. All bone metabolism variables in serum (alkaline phosphatase, osteocalcin, procollagen 1 C-terminal peptide, collagen 1 teleopeptide) and urine (deoxypyridinoline) indicated that there was a decrease in bone turnover. All patients experienced beneficial effects and the younger patients reported a major improvement in well-being, pain, and mobility without significant side effects. Vertebral remodelling was also seen. Conclusions: APD seems to be an efficient symptomatic treatment for children and adolescents with OI.

Cite

CITATION STYLE

APA

Åström, E., & Söderhäll, S. (2002). Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Archives of Disease in Childhood, 86(5), 356–364. https://doi.org/10.1136/adc.86.5.356

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free